Organon

#NEWS: Our topical cream has received a strong recommendation in the American Academy of Dermatology (AAD)’s first-ever Pediatric Atopic Dermatitis Guidelines and is indicated for children down to 2 years of age with mild, moderate, and severe #AtopicDermatitis. Learn more at the links below. Press release: ogn.llc/6001QC5SR Pediatric guidelines available here: ogn.llc/6006QC5qE #OrganonDermatology #AADGuidelines #AtopicDermatitis #Eczema

At the AAD Annual Meeting, we’re excited to debut new analysis of Phase 3 pooled data for one of our dermatology treatments evaluating skin clearance and itch improvement in atopic dermatitis patients down to 2 years of age. Read more: ogn.llc/6044QvZcs #AAD2026

At the @AAAAI_org Annual Meeting, we’re excited to unveil new sub-analysis for one of our dermatology treatments evaluating sleep-related measures in pediatric patients down to 2 years of age with atopic dermatitis (AD). #AAAAI2026 #OrganonDermatology ogn.llc/6012QbC18

#RegulatoryNews: Today, Organon announced the @US_FDA has approved a supplemental new drug application extending the duration of use for one of our long-acting contraceptive options. The study supporting the approval enrolled a population of women with varying body mass indices. At Organon, we are committed to advancing inclusive and comprehensive women’s healthcare, including expanding access to contraception and increasing available choices. Learn more about the updated label: lnkd.in/ehSDuBjr Intended for U.S. audiences only. #Contraception #BirthControl #Media #Investors

#NEWS Today, Organon announced the approval of our novel dermatology treatment for #PlaquePsoriasis and #AtopicDermatitis in the United Arab Emirates (UAE). We’re proud to bring this #dermatology treatment option to healthcare professionals and patients. #OrganonDermatology

#NEWS We are proud to announce with @HenliusBiotech the @US_FDA approved the first interchangeable #biosimilar for patients with certain types of breast cancer. This marks a major step forward as we continue to deliver on our mission of providing quality and potentially more affordable treatment options for patients, and in the case of this approval, expanding access to treatments for diseases that disproportionately impact women, including #BreastCancer, one of the most common cancers among women in the US. Learn more about this milestone: ogn.llc/6015tuQU3 #OrganonBiosimilars

At the @ACAAI Annual Meeting we’re excited to unveil new data about one of our #dermatology treatments for children aged 2 years and older with atopic dermatitis (AD), reinforcing Organon’s commitment to advancing research for patients living with AD. #ACAAI2025 ogn.llc/6014tKnEI

We’re proud to continue our support of the @ASRM_org. At this year’s annual conference, join us at booth 1635 at 10am on Monday, October 27th to discuss expanding access to reproductive technologies and fertility preservation services for active-duty service members and their partners. We’ll be joined by the Military Family Building Coalition, along with leading physicians and policy experts, who will shed light on the medical, logistical, and policy barriers impeding access to robust fertility care. #ASRM2025 #FertilityJourney #HereforHerHealth

#NEWS Organon Canada is the second country globally to launch our novel dermatology treatment for #PlaquePsoriasis. We’re proud to expand our global footprint in #dermatology – continuing our mission to deliver impactful medicines and treatments that help make a difference for both patients and healthcare professionals. #OrganonDermatology

The European Commission has granted marketing authorization for two of our #biosimilars in collaboration with @HenliusBiotech. This announcement follows the recent #FDA approval of these biosimilars, marking another step toward expanding global access to treatments in bone care, including #osteoporosis. Learn more: ogn.llc/6017soynT #OrganonBiosimilars

At Organon, we’re committed to supporting the adoption of biosimilars across the healthcare system. As part of that commitment, we’re sponsoring a session at @ASBMR: Organon Biosimilars in Focus: From Biosimilarity to Clinical Application. Learn more: ogn.llc/6010se9mC #OrganonBiosimilars #ASBMR2025 #AllinOnBiosimilars

The @US_FDA has approved two of our #biosimilars in collaboration with @HenliusBiotech. This announcement marks the first regulatory approval with Henlius for these products and is an important milestone toward expanding patient access to treatment options for conditions such as #osteoporosis and cancer-related bone disease. This approval underscores Organon’s unwavering commitment to making treatments more accessible by offering quality, cost-effective options for patients, and in the case of this approval, helping to create a sustainable future for the care of bone health. Learn more: ogn.llc/6011sdjdl

From the builders of our cities to the innovators in our industries, today we celebrate the incredible contributions that build our communities and drive progress. #LaborDay

This year marked our very first time at the @nationaleczema Eczema Expo—and wow, what an unforgettable experience! 💙 From the moment we arrived, we were moved by the energy and passion of the #eczema community. ✨ Expo Highlight ✨ 📸 Our booth included The Polaroid Project—an interactive space where attendees captured their favorite part of the expo. The reflections shared and heartfelt stories left us feeling incredibly inspired and more committed to supporting this community of patients, caregivers, and healthcare professionals. #EczemaExpo25 #ExpoFOMO #PediatricDermatology #AtopicDermatitis #Dermatology

#NEWS: Our topical cream has received a strong recommendation in the American Academy of Dermatology’s updated guidelines for adults with moderate to severe #AtopicDermatitis. Learn more at the links below. @AADskin Press release: organon.com/news/organons-… Updated guidelines: sciencedirect.com/science/articl… #ClinicalDermatology #eczema

Today, our U.S.-based Founders celebrate the Fourth of July—a time to reflect on our shared history and honor those who fought for our right to gather, celebrate, and be together. Whether you’re grilling burgers in the backyard, watching fireworks light up the night sky, or spending time with loved ones, we wish you a happy and healthy holiday. #IndependenceDay #4thofJuly

Fathers play a critical role in supporting women’s health. Even small, everyday actions like buying tampons or having open conversations about mental and sexual health can help eliminate stigma and empower daughters. #HappyFathersDay

#News Organon and Evvy are collaborating to help offer a patient-first experience for women suffering from #BacterialVaginosis (BV), the most common vaginal condition in women of reproductive age in the US, affecting approximately 21 million women. Together, we aim to help women more conveniently access the treatments she needs. Read the news: ogn.llc/6018SSz62 #BV #FeminineCare #HereforHerHealth #WomensHealth

The @FDA has granted #interchangeability designation to @SamsungBioepis and Organon for one of our #biosimilars, letting pharmacists substitute a biosimilar without a new Rx, subject to state law, potentially making medication more accessible for patients. Learn more: ogn.llc/6012S9MNO